ClinicalTrials.gg
CompletedNCT03196427Updated May 13, 2026Results posted

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

A Phase 2 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Completed at 23 sites in 7 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
27th of 38
59 · median 110
Started
2018
with 1 other
Phase 2
5 of 38
none open now
Registered
18th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 27th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 18th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.

Read the detailed description

The drug being tested in this study is called Vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD.

This study will look at the long-term safety profile in participants who take vedolizumab IV. Participants will continue receiving the same dose assigned from the parent study MLN0002-2003 [NCT03138655], which will remain blinded until week 40.

The dosing regimen selected for the long-term study is intended to maintain clinical response at the lowest possible exposure.

At the discretion of the investigator, participants receiving the low dose (150 or 100 milligram [mg]) of vedolizumab IV may be escalated to the high dose (300 or 200 mg) if the participants demonstrate disease worsening at 2 consecutive visits (scheduled or unscheduled).

Participants who experience continued disease worsening during the study despite being administered vedolizumab 300 or 200 mg every 8 weeks (Q8W) will be discontinued from the study.

Study duration will be until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug, the participant withdraws from the study, or the sponsor decides to close the study (up to approximately 8 years).

03

Conditions studied

  • Ulcerative Colitis
  • Crohn's Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female with UC or CD and was between 2 to 17 years, inclusive, at the time of randomization for Study MLN0002-2003.

    (Note: A participant remains eligible to participate in this study after they reach 18 years of age if they continue to meet the inclusion criteria and do not meet any exclusion criteria.)

  2. Has completed Study MLN0002-2003 and, at Week 22, achieved clinical response as defined by a reduction of partial Mayo score of >=2 points and >=25% from Baseline, or a reduction of the Paediatric Ulcerative Colitis Activity Index (PUCAI) of >=20 points from baseline for participants with UC; or a reduction of the CDAI as defined by a >=70-point decrease from Baseline or a decrease of Pediatric Crohn's Disease Activity Index (PCDAI) of >=15 points for participants with CD.
  3. May be receiving a therapeutic dose of the following drugs:

    • Oral 5-aminosalicylic acid (5-ASA) compounds.
    • Oral therapy (prednisone or equivalent steroid at a dose less than or equal to [\<=] 50 milligram per day [mg/day]) provided the participant was receiving this medication during prior participation in MLN0002-2003.
    • Topical (rectal) treatment with 5-ASA or corticosteroids.
    • Probiotics (example, Saccharomyces boulardii).
    • Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
    • Antibiotics used for the treatment of CD (i.e., ciprofloxacin, metronidazole).
    • Azathioprine (AZA) or 6-mercaptopurine (6-MP) or methotrexate (MTX), provided the participant was receiving this medication during prior participation in MLN0002-2003.
  4. The participant's vaccinations are up to date as per inclusion criteria number 10 in MLN0002-2003.

Exclusion criteria

Exclusion Criteria:

  1. Is female and is lactating or pregnant.
  2. Has or allergies to vedolizumab or any of its .
  3. Has withdrawn from Study MLN0002-2003.
  4. Has developed any new unstable or uncontrolled cardiovascular, heart failure moderate to severe (New York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  5. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist prior to the administration of the first dose of study drug.
  6. Currently requires major surgical intervention for UC or CD (example, bowel resection), or is anticipated to require major surgical intervention for UC or CD during the study.
  7. Has other serious comorbidities that will limit his or her ability to complete the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Vedolizumab High Dose Group

    Participants with UC or CD having baseline weight of greater than or equal to (\>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (\<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).

    Drug: Vedolizumab

  • Experimental
    Vedolizumab Low Dose Group

    Participants with UC or CD having baseline weight of \>= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of \< 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).

    Drug: Vedolizumab

Interventions

  • Vedolizumab intravenous infusion

    Also known as: MLN0002, ENTYVIO, KYNTELES

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    AE defined as any untoward medical occurrence in clinical investigation participants administered drug; it does not necessarily have to have causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it was considered related to the drug. TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug, or an already-present AE that worsened in intensity or frequency following the treatment start, occurring from the first dose of study drug to the day of last dose of study drug.

    Time frame: From first dose of study drug up to end of follow up (up to 6.8 years)

Secondary outcomes

  1. Percentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score

    Clinical response was defined as a continued reduction in complete Mayo score of \>=3 points and \>=30 percent (%) from baseline (at initiation of MLN0002-2003) and continued decrease in rectal bleeding subscore of \>=1 point from baseline, or absolute rectal bleeding subscore of less than or equal to (\<=1) point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings on endoscopy and physician rating of disease activity, each graded from 0 to 3 where 0 indicated normal and 3 indicated more severe disease. These scores were summed to give a total score range of 0 to 12; where higher scores indicated more severe disease.

    Time frame: At Week 32

  2. Percentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 32

    Maintenance of clinical response based on SES-CD and CDAI was defined as a 50% reduction in SES-CD score on endoscopy compared to the baseline endoscopy \[at initiation of MLN0002-2003 (NCT03138655)\]; and continued reduction in CDAI that is a \>= 70 point decrease from the baseline CDAI score at the initiation of MLN0002-2003 (NCT03138655). CDAI was a research tool used to quantify the symptoms of participants with Crohn's disease. SES-CD consisted of 3 variables: ulcer size, ulcerated and affected surfaces and presence of narrowing each graded from 0 to 3 with score of 0 means no colonic lesions or mucosal healing, and SES-CD greater than (\>) 1 indicated the presence of mucosal lesions.

    Time frame: At Week 32

  3. Time to Major Inflammatory Bowel Disease (IBD) - Related Events

    Time to major IBD-related events was defined as time from study treatment start to first major IBD-related hospitalization, surgery, or procedure due to UC and CD.

    Time frame: Up to 6.8 years

  4. Change From Baseline in IMPACT-III - Total Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III used a 5-point Likert scale ranging from 1 to 5 for all answers. The total score was obtained by summing individual domain scores. The total score ranged from 35 to 175, with higher scores suggesting better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  5. Change From Baseline in IMPACT-III - Bowel Symptoms Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The Bowel Symptoms domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The bowel symptoms domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  6. Change From Baseline in IMPACT-III - Systemic Symptoms Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The systemic symptoms domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The systemic symptoms domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  7. Change From Baseline in IMPACT-III - Social Functioning Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The social functioning domain consisted of 12 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The social functioning domain score ranged from 12 to 60, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  8. Change From Baseline in IMPACT-III - Body Image Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The body image domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The body image domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  9. Change From Baseline in IMPACT-III - Treatment/Interventions Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The treatment/interventions domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The treatment/interventions domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  10. Change From Baseline in IMPACT-III - Emotional Functioning Domain Score

    The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The emotional functioning domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The emotional functioning domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312

  11. Height Velocity at Week 48 and Every 48 Weeks

    Height velocity (centimeter per year \[cm/year\]) was calculated as the change in height divided by the duration \[time between the two height measures\].

    Time frame: At Weeks 48, 96, 144, 192, 240, 288, and 336

  12. Change From Baseline in Height

    Change from baseline in height was reported.

    Time frame: Baseline, Weeks 48, 96, 144, 192, 240, 288, 336

  13. Change From Baseline in Weight

    Change from baseline in weight was reported.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336

  14. Change From Baseline in Body Mass Index (BMI)

    BMI was calculated as Weight (in kilograms)/height (in meters square).

    Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336

  15. Percentage of Participants Who Achieved Tanner Stage V at or Before Age 16 (in Females) or Age 17 (in Males)

    Tanner Stage Evaluation was a scale used to evaluate growth parameters standardized for age, sex, and pubertal development. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Tanner stage was assessed at or before age 16 years for females or 17 years for males.

    Time frame: Up to 6.8 years

07

Results

Posted Mar 13, 2026

Participant flow

A total of 59 participants with ulcerative colitis (UC) or Crohn's disease (CD) took part in the study across 34 investigative sites in Belgium, United States, France, Hungary, Israel, Poland, Ukraine, and United Kingdom from 30 July 2018 to 17 July 2025.

Participant flow — Overall Study
MilestoneUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Started5977107410
Uc participants: dose escalated to vedolizumab 300 mg22008000
Cd participants: dose escalated to vedolizumab 300 mg00220020
Safety analysis set365527210
Completed24526213
Not completed35254537
Withdrew: Adverse event23033302
Withdrew: Protocol violation00000001
Withdrew: Lost to follow-up11000000
Withdrew: Withdrawal by subject00211022
Withdrew: Other01010212

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

AE defined as any untoward medical occurrence in clinical investigation participants administered drug; it does not necessarily have to have causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it was considered related to the drug. TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug, or an already-present AE that worsened in intensity or frequency following the treatment start, occurring from the first dose of study drug to the day of last dose of study drug.

Time frame:
From first dose of study drug up to end of follow up (up to 6.8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)10083.3100100100100100100100100
SecondaryPercentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score

Clinical response was defined as a continued reduction in complete Mayo score of \>=3 points and \>=30 percent (%) from baseline (at initiation of MLN0002-2003) and continued decrease in rectal bleeding subscore of \>=1 point from baseline, or absolute rectal bleeding subscore of less than or equal to (\<=1) point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings on endoscopy and physician rating of disease activity, each graded from 0 to 3 where 0 indicated normal and 3 indicated more severe disease. These scores were summed to give a total score range of 0 to 12; where higher scores indicated more severe disease.

Time frame:
At Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score
percentage of participantsUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mg
Percentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score50.0 (0.094 to 0.992)75.0 (0.541 to —)10050
SecondaryPercentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 32

Maintenance of clinical response based on SES-CD and CDAI was defined as a 50% reduction in SES-CD score on endoscopy compared to the baseline endoscopy \[at initiation of MLN0002-2003 (NCT03138655)\]; and continued reduction in CDAI that is a \>= 70 point decrease from the baseline CDAI score at the initiation of MLN0002-2003 (NCT03138655). CDAI was a research tool used to quantify the symptoms of participants with Crohn's disease. SES-CD consisted of 3 variables: ulcer size, ulcerated and affected surfaces and presence of narrowing each graded from 0 to 3 with score of 0 means no colonic lesions or mucosal healing, and SES-CD greater than (\>) 1 indicated the presence of mucosal lesions.

Time frame:
At Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 32
percentage of participantsCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Percentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 3283.328.6050.0
SecondaryTime to Major Inflammatory Bowel Disease (IBD) - Related Events

Time to major IBD-related events was defined as time from study treatment start to first major IBD-related hospitalization, surgery, or procedure due to UC and CD.

Time frame:
Up to 6.8 years
Reported as:
Median · days
Time to Major Inflammatory Bowel Disease (IBD) - Related Events
daysUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Time to Major Inflammatory Bowel Disease (IBD) - Related EventsNA (482.00 to NA)NA (NA to NA)NA (NA to NA)NA (78.00 to NA)NA (NA to NA)2058.00 (32.00 to NA)NA (NA to NA)NA (49.00 to NA)NA (794.00 to NA)NA (NA to NA)
SecondaryChange From Baseline in IMPACT-III - Total Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III used a 5-point Likert scale ranging from 1 to 5 for all answers. The total score was obtained by summing individual domain scores. The total score ranged from 35 to 175, with higher scores suggesting better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Total Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—1.0 ± 0.0013.0 ± 7.0710.0 ± NA9.0 ± 18.38-4.3 ± 6.978.0 ± NA2.7 ± 10.39-2.9 ± 7.42-6.3 ± 2.08
Change at Week 48—6.0 ± NA8.0 ± NA19.0 ± NA2.5 ± 7.78-6.0 ± 10.7316.0 ± NA11.0 ± 19.96-1.2 ± 9.50-1.3 ± 3.79
Change at Week 72—-5.0 ± NA11.0 ± NA12.0 ± NA10.5 ± 16.26-1.2 ± 5.0217.0 ± NA19.7 ± 24.54-0.4 ± 5.834.0 ± 9.17
Change at Week 96—2.0 ± NA18.0 ± NA8.0 ± NA13.0 ± 16.97-3.4 ± 13.5822.0 ± NA17.3 ± 37.872.1 ± 9.12-1.5 ± 10.61
Change at Week 120—-8.0 ± NA24.0 ± NA32.0 ± NA11.0 ± 5.661.6 ± 7.028.0 ± NA-2.7 ± 3.79-7.3 ± 10.75-3.5 ± 12.02
Change at Week 144—-4.0 ± NA31.0 ± NA-10.0 ± NA14.0 ± 14.141.8 ± 14.17-6.0 ± NA0.7 ± 10.02-6.0 ± 6.63-1.0 ± 0.00
Change at Week 168—1.0 ± NA21.0 ± NA42.0 ± NA7.5 ± 12.020.3 ± 14.41-6.0 ± NA8.7 ± 13.32-4.3 ± 12.56-3.0 ± 4.24
Change at Week 192—-8.0 ± NA—29.0 ± NA21.0 ± NA4.8 ± 16.647.0 ± NA8.3 ± 7.02-5.8 ± 13.26-12.5 ± 19.09
Change at Week 216—-5.0 ± NA—21.0 ± NA14.5 ± 13.443.8 ± 15.004.0 ± NA2.00 ± 0.00-5.7 ± 18.10-0.5 ± 6.36
Change at Week 240—-1.0 ± NA——12.5 ± 16.265.0 ± 9.9015.0 ± NA0.0 ± 5.66-5.8 ± 18.06-4.5 ± 10.61
Change at Week 264—-3.0 ± NA——9.5 ± 10.618.5 ± 20.51—9.00 ± NA2.0 ± 12.771.0 ± 8.49
Change at Week 288————-2.0 ± NA17.0 ± 8.49—5.0 ± NA6.5 ± 13.443.0 ± NA
Change at Week 312————2.0 ± NA-7.0 ± NA—12.0 ± NA4.5 ± 9.191.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Bowel Symptoms Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The Bowel Symptoms domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The bowel symptoms domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Bowel Symptoms Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—2.5 ± 0.713.0 ± 2.836.0 ± NA1.0 ± 2.830.7 ± 1.802.0 ± NA1.0 ± 4.90-0.6 ± 2.24-2.0 ± 2.65
Change at Week 48—2.0 ± NA0.0 ± NA6.0 ± NA-1.0 ± 2.83-1.3 ± 3.274.0 ± NA3.4 ± 3.44-0.2 ± 2.91-1.3 ± 3.21
Change at Week 72—2.0 ± NA3.0 ± NA6.0 ± NA0.5 ± 0.71-0.4 ± 1.345.0 ± NA5.0 ± 4.58-0.1 ± 2.530.7 ± 1.53
Change at Week 96—2.0 ± NA4.0 ± NA2.0 ± NA1.5 ± 2.12-0.6 ± 2.614.0 ± NA2.7 ± 6.350.7 ± 1.500.0 ± 1.41
Change at Week 120—1.0 ± NA6.0 ± NA7.0 ± NA0.5 ± 2.120.6 ± 2.973.0 ± NA-2.7 ± 1.53-1.6 ± 3.541.0 ± 2.83
Change at Week 144—3.0 ± NA6.0 ± NA0.0 ± NA1.0 ± 2.831.3 ± 3.502.0 ± NA-1.0 ± 3.00-1.0 ± 2.901.5 ± 0.71
Change at Week 168—3.0 ± NA6.0 ± NA10.0 ± NA1.0 ± 1.410.3 ± 2.501.0 ± NA2.3 ± 3.06-0.7 ± 3.881.0 ± 0.00
Change at Week 192—2.0 ± NA—7.0 ± NA3.0 ± NA2.0 ± 3.652.0 ± NA2.3 ± 3.51-1.3 ± 5.16-4.5 ± 7.78
Change at Week 216—1.0 ± NA—6.0 ± NA1.5 ± 2.121.5 ± 2.650.0 ± NA1.5 ± 3.54-1.7 ± 5.750.0 ± 2.83
Change at Week 240—3.0 ± NA——1.5 ± 2.123.0 ± 4.244.0 ± NA0.0 ± 4.24-0.3 ± 4.800.0 ± 2.83
Change at Week 264—2.0 ± NA——0.5 ± 3.541.5 ± 3.54—3.0 ± NA1.7 ± 3.790.5 ± 2.12
Change at Week 288————-4.0 ± NA5.0 ± 1.41—5.0 ± NA2.0 ± 5.661.0 ± NA
Change at Week 312————-3.0 ± NA0.0 ± NA—4.0 ± NA4.0 ± 4.240.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Systemic Symptoms Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The systemic symptoms domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The systemic symptoms domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Systemic Symptoms Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—2.0 ± 1.413.0 ± 5.663.0 ± NA0.0 ± 2.83-1.1 ± 1.860.0 ± NA0.9 ± 1.77-0.3 ± 1.41-0.3 ± 1.53
Change at Week 48—1.0 ± NA2.0 ± NA4.0 ± NA-1.0 ± 1.41-0.5 ± 1.383.0 ± NA1.4 ± 2.41-0.3 ± 1.410.3 ± 0.58
Change at Week 72—0.0 ± NA6.0 ± NA1.0 ± NA-0.5 ± 4.95-1.8 ± 3.272.0 ± NA2.3 ± 3.21-0.4 ± 0.920.7 ± 1.15
Change at Week 96—3.0 ± NA6.0 ± NA-1.0 ± NA0.5 ± 3.54-0.4 ± 2.073.0 ± NA1.3 ± 4.16-0.4 ± 2.07-0.5 ± 0.71
Change at Week 120—0.0 ± NA7.0 ± NA1.0 ± NA0.0 ± 1.41-0.6 ± 1.140.0 ± NA1.0 ± 1.73-0.8 ± 3.20-1.5 ± 2.12
Change at Week 144—1.0 ± NA6.0 ± NA1.0 ± NA1.0 ± 2.830.8 ± 2.993.0 ± NA0.7 ± 0.580.0 ± 1.55-0.5 ± 0.71
Change at Week 168—1.0 ± NA6.0 ± NA3.0 ± NA-2.5 ± 4.950.0 ± 3.37-1.0 ± NA1.0 ± 1.73-1.2 ± 3.87-2.0 ± 0.00
Change at Week 192—2.0 ± NA—3.0 ± NA3.0 ± NA0.0 ± 2.161.0 ± NA1.0 ± 1.00-0.2 ± 2.64-3.5 ± 4.95
Change at Week 216—0.0 ± NA—3.0 ± NA0.5 ± 2.12-1.3 ± 2.751.0 ± NA0.0 ± 2.830.2 ± 2.14-1.0 ± 1.41
Change at Week 240—2.0 ± NA——0.5 ± 2.120.0 ± 0.002.0 ± NA2.0 ± 1.41-0.5 ± 2.07-1.5 ± 2.12
Change at Week 264—0.00 ± NA——-0.5 ± 0.710.5 ± 3.54—1.0 ± NA-1.3 ± 2.520.0 ± 0.00
Change at Week 288————-4.0 ± NA0.5 ± 0.71—1.0 ± NA0.0 ± 0.000.0 ± NA
Change at Week 312————-4.0 ± NA-5.0 ± NA—1.0 ± NA0.0 ± 0.000.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Social Functioning Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The social functioning domain consisted of 12 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The social functioning domain score ranged from 12 to 60, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Social Functioning Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—0.0 ± 1.413.0 ± 7.070.0 ± NA3.5 ± 3.54-1.7 ± 2.751.0 ± NA1.1 ± 3.98-1.1 ± 3.22-3.3 ± 1.53
Change at Week 48—2.0 ± NA3.0 ± NA1.0 ± NA1.0 ± 2.83-0.8 ± 2.713.0 ± NA3.4 ± 7.020.1 ± 4.57-0.7 ± 4.04
Change at Week 72—-4.0 ± NA2.0 ± NA-2.0 ± NA6.0 ± 4.24-0.2 ± 2.286.0 ± NA5.7 ± 10.600.3 ± 2.38-1.0 ± 3.61
Change at Week 96—2.0 ± NA6.0 ± NA-4.0 ± NA4.5 ± 3.54-1.8 ± 3.706.0 ± NA7.7 ± 11.721.0 ± 3.65-2.0 ± 7.07
Change at Week 120—-2.0 ± NA4.0 ± NA7.0 ± NA4.0 ± 2.830.6 ± 1.144.0 ± NA0.0 ± 1.73-0.1 ± 1.77-2.0 ± 5.66
Change at Week 144—0.0 ± NA9.0 ± NA-8.0 ± NA5.0 ± 4.24-0.8 ± 3.20-5.0 ± NA0.7 ± 2.31-0.5 ± 2.17-1.0 ± 4.24
Change at Week 168—0.0 ± NA3.0 ± NA13.0 ± NA4.5 ± 6.36-0.5 ± 3.700.0 ± NA2.3 ± 6.510.2 ± 3.76-2.5 ± 3.54
Change at Week 192—-2.0 ± NA—6.0 ± NA9.0 ± NA-0.5 ± 5.452.0 ± NA-0.7 ± 3.21-0.3 ± 0.82-3.0 ± 2.83
Change at Week 216—-1.0 ± NA—2.0 ± NA4.0 ± 2.830.3 ± 4.031.0 ± NA-2.0 ± 0.00-1.3 ± 3.98-2.0 ± 1.41
Change at Week 240—-2.0 ± NA——3.5 ± 9.190.0 ± 2.836.0 ± NA-1.0 ± 0.00-1.8 ± 3.76-3.5 ± 3.54
Change at Week 264—2.0 ± NA——4.5 ± 4.951.5 ± 4.95—2.0 ± NA0.3 ± 3.21-3.0 ± 5.66
Change at Week 288————1.0 ± NA3.5 ± 3.54—-1.0 ± NA0.0 ± 0.00-2.0 ± NA
Change at Week 312————2.0 ± NA-2.0 ± NA—1.0 ± NA-1.5 ± 2.12-1.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Body Image Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The body image domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The body image domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Body Image Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—-2.5 ± 0.710.5 ± 0.71-2.0 ± NA1.5 ± 2.12-0.3 ± 0.49-1.0 ± NA-0.1 ± 1.570.6 ± 1.81-1.7 ± 0.58
Change at Week 48—-1.0 ± NA-1.0 ± NA-2.0 ± NA1.5 ± 3.54-0.2 ± 1.170.0 ± NA-0.4 ± 2.610.1 ± 0.780.0 ± 2.00
Change at Week 72—-3.0 ± NA0.0 ± NA-1.0 ± NA2.0 ± 2.830.8 ± 2.17-3.0 ± NA0.7 ± 1.15-0.6 ± 1.303.3 ± 1.15
Change at Week 96—-2.0 ± NA0.0 ± NA0.0 ± NA1.5 ± 2.121.0 ± 2.00-1.0 ± NA1.7 ± 6.66-0.3 ± 1.381.0 ± 1.41
Change at Week 120—-5.0 ± NA3.0 ± NA1.0 ± NA1.5 ± 2.120.8 ± 1.64-4.0 ± NA0.3 ± 3.79-0.5 ± 2.201.0 ± 0.00
Change at Week 144—-5.0 ± NA4.0 ± NA-6.0 ± NA1.0 ± 1.410.5 ± 1.00-5.0 ± NA0.7 ± 2.08-0.8 ± 1.941.0 ± 0.00
Change at Week 168—-3.0 ± NA3.0 ± NA0.0 ± NA1.5 ± 2.120.5 ± 1.00-6.0 ± NA1.3 ± 2.890.3 ± 1.750.5 ± 0.71
Change at Week 192—-4.0 ± NA—0.0 ± NA0.0 ± NA1.3 ± 1.50-4.0 ± NA1.7 ± 2.52-0.3 ± 2.420.0 ± 0.00
Change at Week 216—0.0 ± NA—-1.0 ± NA2.0 ± 1.410.8 ± 0.96-4.0 ± NA0.0 ± 4.240.3 ± 2.162.0 ± 1.41
Change at Week 240—-3.0 ± NA——2.00 ± 0.000.5 ± 0.71-4.0 ± NA-2.0 ± 2.830.3 ± 2.161.0 ± 1.41
Change at Week 264—-3.0 ± NA——1.0 ± 1.410.0 ± 1.41—-3.0 ± NA-0.3 ± 2.522.5 ± 0.71
Change at Week 288————2.0 ± NA1.5 ± 0.71—-3.0 ± NA0.0 ± 2.832.0 ± NA
Change at Week 312————3.0 ± NA0.0 ± NA—-1.0 ± NA-1.0 ± 2.830.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Treatment/Interventions Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The treatment/interventions domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The treatment/interventions domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Treatment/Interventions Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—-1.0 ± 1.412.0 ± 1.410.0 ± NA1.0 ± 2.830.1 ± 0.901.0 ± NA-1.3 ± 1.80-0.3 ± 1.121.0 ± 1.00
Change at Week 48—1.0 ± NA3.0 ± NA3.0 ± NA0.5 ± 0.71-0.7 ± 1.210.0 ± NA0.4 ± 2.19-0.1 ± 0.780.7 ± 1.53
Change at Week 72—0.0 ± NA0.0 ± NA5.0 ± NA-0.5 ± 2.120.0 ± 1.220.0 ± NA0.7 ± 2.31-0.1 ± 1.361.0 ± 1.00
Change at Week 96—-1.0 ± NA2.0 ± NA3.0 ± NA1.0 ± 1.41-0.2 ± 1.791.0 ± NA0.0 ± 3.460.3 ± 1.500.0 ± 0.00
Change at Week 120—-1.0 ± NA1.0 ± NA6.0 ± NA0.0 ± 0.000.0 ± 1.22-1.0 ± NA-3.3 ± 1.15-0.4 ± 2.070.0 ± 0.00
Change at Week 144—-1.0 ± NA3.0 ± NA2.0 ± NA0.5 ± 0.710.8 ± 1.71-1.0 ± NA-1.3 ± 3.06-0.1 ± 2.190.5 ± 0.71
Change at Week 168—0.0 ± NA2.0 ± NA5.0 ± NA0.5 ± 0.710.3 ± 1.710.0 ± NA-0.3 ± 3.21-0.7 ± 2.251.0 ± 0.00
Change at Week 192—-2.0 ± NA—4.0 ± NA0.0 ± NA1.0 ± 0.82-1.0 ± NA0.3 ± 1.53-1.2 ± 2.480.5 ± 0.71
Change at Week 216—-1.0 ± NA—4.0 ± NA1.5 ± 2.121.5 ± 1.911.0 ± NA-0.5 ± 0.71-0.7 ± 3.080.5 ± 0.71
Change at Week 240—-1.0 ± NA——0.5 ± 0.711.0 ± 1.413.0 ± NA0.0 ± 1.41-0.2 ± 2.640.5 ± 0.71
Change at Week 264—-2.0 ± NA——0.5 ± 0.711.5 ± 2.12—2.0 ± NA0.7 ± 0.581.0 ± 0.00
Change at Week 288————0.0 ± NA1.5 ± 0.71—-1.0 ± NA1.5 ± 2.122.0 ± NA
Change at Week 312————0.0 ± NA0.0 ± NA—2.0 ± NA1.0 ± 1.412.0 ± NA
SecondaryChange From Baseline in IMPACT-III - Emotional Functioning Domain Score

The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The emotional functioning domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The emotional functioning domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Reported as:
Mean · score on a scale
Change From Baseline in IMPACT-III - Emotional Functioning Domain Score
score on a scaleUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Change at Week 24—0.0 ± 0.001.5 ± 2.123.0 ± NA2.0 ± 4.24-2.0 ± 2.895.0 ± NA1.1 ± 2.79-1.1 ± 3.020.0 ± 1.73
Change at Week 48—1.0 ± NA1.0 ± NA7.0 ± NA1.5 ± 2.12-2.5 ± 6.356.0 ± NA2.8 ± 4.66-0.8 ± 4.09-0.3 ± 1.53
Change at Week 72—0.0 ± NA0.0 ± NA3.0 ± NA3.0 ± 1.410.4 ± 4.047.0 ± NA5.3 ± 4.930.6 ± 3.20-0.7 ± 1.53
Change at Week 96—-2.0 ± NA0.0 ± NA8.0 ± NA4.0 ± 4.24-1.4 ± 5.689.0 ± NA4.0 ± 7.550.9 ± 3.530.0 ± 0.00
Change at Week 120—-1.0 ± NA3.0 ± NA10.0 ± NA5.0 ± 1.410.2 ± 3.276.0 ± NA2.0 ± 2.00-1.9 ± 5.00-2.0 ± 1.41
Change at Week 144—-2.0 ± NA3.0 ± NA1.0 ± NA5.5 ± 2.12-0.8 ± 5.120.0 ± NA1.0 ± 3.61-2.7 ± 3.78-2.5 ± 4.95
Change at Week 168—0.0 ± NA1.0 ± NA11.0 ± NA2.5 ± 0.71-0.3 ± 5.800.0 ± NA2.0 ± 2.65-2.3 ± 5.79-1.0 ± 0.00
Change at Week 192—-4.0 ± NA—9.0 ± NA6.0 ± NA1.0 ± 6.167.0 ± NA3.7 ± 2.52-2.5 ± 6.25-2.0 ± 2.83
Change at Week 216—-4.0 ± NA—7.0 ± NA5.0 ± 2.831.0 ± 5.355.0 ± NA3.0 ± 2.83-2.5 ± 7.310.0 ± 0.00
Change at Week 240—0.0 ± NA——4.5 ± 2.120.5 ± 0.714.0 ± NA1.0 ± 4.24-3.3 ± 7.45-1.0 ± 1.41
Change at Week 264—-2.0 ± NA——3.5 ± 2.123.5 ± 4.95—4.0 ± NA1.0 ± 3.000.0 ± 0.00
Change at Week 288————3.0 ± NA5.0 ± 5.66—4.0 ± NA3.0 ± 2.830.0 ± NA
Change at Week 312————4.0 ± NA0.0 ± NA—5.0 ± NA2.0 ± 2.830.0 ± NA
SecondaryHeight Velocity at Week 48 and Every 48 Weeks

Height velocity (centimeter per year \[cm/year\]) was calculated as the change in height divided by the duration \[time between the two height measures\].

Time frame:
At Weeks 48, 96, 144, 192, 240, 288, and 336
Reported as:
Mean · cm/year
Height Velocity at Week 48 and Every 48 Weeks
cm/yearUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
At Week 480.02 ± 0.0060.02 ± 0.0070.02 ± 0.0050.01 ± 0.0030.01 ± 0.0080.01 ± 0.0100.01 ± 0.0070.01 ± 0.008
At Week 960.02 ± 0.0030.02 ± 0.0060.02 ± 0.0040.02 ± 0.0040.01 ± 0.0070.01 ± 0.0110.01 ± 0.0070.01 ± 0.007
At Week 1440.02 ± 0.0030.02 ± 0.0040.02 ± 0.0020.02 ± 0.0060.01 ± 0.0080.01 ± 0.0110.00 ± 0.0010.01 ± 0.008
At Week 1920.02 ± 0.0030.01 ± 0.0040.02 ± 0.0010.02 ± 0.0050.01 ± 0.0080.01 ± 0.0100.00 ± 0.0010.01 ± 0.007
At Week 2400.02 ± 0.0030.02 ± 0.0060.02 ± 0.0010.02 ± NA0.01 ± 0.0070.01 ± 0.0100.00 ± 0.0010.01 ± 0.007
At Week 288—0.02 ± 0.0010.02 ± NA—0.01 ± 0.0040.01 ± 0.0080.00 ± NA0.01 ± NA
At Week 336————0.01 ± NA———
SecondaryChange From Baseline in Height

Change from baseline in height was reported.

Time frame:
Baseline, Weeks 48, 96, 144, 192, 240, 288, 336
Reported as:
Mean · cm
Change From Baseline in Height
cmUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Change at Week 485.80 ± 1.8786.44 ± 2.2898.30 ± 1.6495.08 ± 1.1794.64 ± 2.7413.22 ± 3.3824.48 ± 2.4502.83 ± 2.658
Change at Week 9612.80 ± 2.33911.83 ± 4.20915.15 ± 2.95412.28 ± 2.5208.78 ± 4.6878.18 ± 7.4735.17 ± 4.7264.77 ± 4.866
Change at Week 14420.65 ± 3.32315.50 ± 3.88820.23 ± 2.45220.03 ± 6.47312.46 ± 7.7919.73 ± 10.6754.15 ± 0.9197.85 ± 7.861
Change at Week 19225.90 ± 3.39419.84 ± 6.00624.02 ± 1.57425.87 ± 6.35814.26 ± 10.93812.53 ± 14.0934.15 ± 0.9199.48 ± 9.566
Change at Week 24032.00 ± 4.24326.48 ± 9.71029.00 ± 2.34526.00 ± NA15.57 ± 12.52918.73 ± 16.8394.25 ± 1.06112.70 ± 11.801
Change at Week 288—39.75 ± 1.76833.00 ± NA—21.60 ± 9.00225.50 ± 15.4153.50 ± NA25.80 ± NA
Change at Week 336————29.00 ± NA———
SecondaryChange From Baseline in Weight

Change from baseline in weight was reported.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336
Reported as:
Mean · kg
Change From Baseline in Weight
kgUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Change at Week 241.40 ± 1.2592.44 ± 1.8132.31 ± 1.5190.88 ± 0.4352.04 ± 4.477-1.10 ± 4.1962.00 ± 7.5791.73 ± 4.797
Change at Week 483.03 ± 1.9175.93 ± 4.0094.95 ± 2.5362.45 ± 1.0635.78 ± 6.6411.27 ± 7.4817.70 ± 5.2273.75 ± 5.496
Change at Week 724.30 ± 2.2768.44 ± 4.8737.00 ± 4.7823.58 ± 1.2428.27 ± 8.2094.66 ± 11.60212.63 ± 7.2285.48 ± 5.775
Change at Week 965.90 ± 3.11910.03 ± 5.3478.80 ± 4.9645.73 ± 1.99911.61 ± 10.1375.88 ± 13.03110.57 ± 2.6636.68 ± 11.022
Change at Week 1209.45 ± 5.72812.11 ± 5.12810.42 ± 4.5487.70 ± 2.45112.14 ± 10.8129.58 ± 14.8159.35 ± 3.4657.63 ± 11.213
Change at Week 14410.65 ± 5.44512.72 ± 3.91612.73 ± 4.80910.53 ± 4.55414.01 ± 10.77511.30 ± 19.53910.30 ± 2.9709.70 ± 16.931
Change at Week 16812.20 ± 2.54612.64 ± 4.65913.62 ± 5.49312.17 ± 4.81914.11 ± 10.80511.93 ± 19.49310.55 ± 4.17210.60 ± 18.655
Change at Week 19215.25 ± 4.59612.54 ± 3.15315.20 ± 6.00113.53 ± 5.18116.01 ± 11.20013.75 ± 23.60411.70 ± 0.9909.65 ± 18.013
Change at Week 21616.50 ± 5.51516.33 ± 1.87515.98 ± 4.27012.45 ± 5.86917.47 ± 10.01915.23 ± 26.23811.40 ± 1.98015.53 ± 19.570
Change at Week 24018.15 ± 6.43518.42 ± 1.95219.20 ± 3.87611.30 ± NA19.74 ± 11.09727.90 ± 26.12112.15 ± 0.91917.33 ± 20.702
Change at Week 264—22.77 ± 0.28921.27 ± 2.81012.70 ± NA18.24 ± 13.13035.67 ± 34.61912.00 ± 0.70744.60 ± NA
Change at Week 288—26.30 ± 0.70725.60 ± NA—24.77 ± 10.38360.55 ± 24.11213.00 ± NA49.60 ± NA
Change at Week 312—30.80 ± NA——27.40 ± 10.18075.60 ± NA13.00 ± NA63.30 ± NA
Change at Week 336————17.00 ± NA———
SecondaryChange From Baseline in Body Mass Index (BMI)

BMI was calculated as Weight (in kilograms)/height (in meters square).

Time frame:
Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI)
kg/m^2UC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Change at Week 240.22 ± 0.8500.31 ± 0.9090.26 ± 0.556-0.10 ± 0.5350.31 ± 1.547-0.60 ± 1.2380.40 ± 2.7870.35 ± 2.076
Change at Week 480.57 ± 1.1151.29 ± 1.5150.83 ± 0.8020.38 ± 0.9671.28 ± 2.644-0.17 ± 2.4601.95 ± 2.2780.93 ± 1.894
Change at Week 720.52 ± 0.7371.80 ± 1.4550.93 ± 1.3840.18 ± 0.8621.66 ± 3.0110.52 ± 3.5523.43 ± 2.3921.12 ± 1.899
Change at Week 960.80 ± 1.1271.89 ± 1.8230.98 ± 1.0890.48 ± 0.7802.53 ± 4.0230.50 ± 3.7422.40 ± 0.4361.60 ± 3.123
Change at Week 1201.80 ± 2.2632.30 ± 1.3541.30 ± 0.9510.63 ± 1.1412.56 ± 4.1691.44 ± 4.1062.30 ± 0.9901.33 ± 2.784
Change at Week 1441.45 ± 1.9092.42 ± 0.8891.77 ± 1.1761.23 ± 1.7042.69 ± 4.1102.10 ± 5.3142.50 ± 0.9901.88 ± 4.522
Change at Week 1681.65 ± 0.0712.22 ± 1.5821.85 ± 1.4081.37 ± 1.7622.37 ± 4.5141.87 ± 6.0582.60 ± 1.4141.85 ± 4.689
Change at Week 1922.75 ± 1.0611.58 ± 1.4702.20 ± 1.6611.33 ± 1.4572.81 ± 4.2732.25 ± 6.1862.95 ± 0.3541.30 ± 4.220
Change at Week 2162.50 ± 1.1312.15 ± 1.8342.16 ± 1.2120.15 ± 0.2123.14 ± 4.0112.50 ± 6.8622.85 ± 0.6362.50 ± 4.151
Change at Week 2402.60 ± 1.5562.55 ± 2.2753.15 ± 1.2661.60 ± NA3.80 ± 4.5486.00 ± 7.4283.10 ± 0.2833.17 ± 4.499
Change at Week 264—2.47 ± 1.4473.70 ± 1.0151.80 ± NA2.70 ± 5.1628.53 ± 10.3883.05 ± 0.2129.40 ± NA
Change at Week 288—3.15 ± 1.9095.00 ± NA—4.87 ± 6.74517.15 ± 14.0713.40 ± NA11.30 ± NA
Change at Week 312—5.60 ± NA——5.53 ± 6.47522.00 ± NA3.40 ± NA16.40 ± NA
Change at Week 336————0.00 ± NA———
SecondaryPercentage of Participants Who Achieved Tanner Stage V at or Before Age 16 (in Females) or Age 17 (in Males)

Tanner Stage Evaluation was a scale used to evaluate growth parameters standardized for age, sex, and pubertal development. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Tanner stage was assessed at or before age 16 years for females or 17 years for males.

Time frame:
Up to 6.8 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Tanner Stage V at or Before Age 16 (in Females) or Age 17 (in Males)
percentage of participantsUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mg
Males——100—100100100100
Females—50——100100—100

Adverse events

Collected over From first dose of study drug up to end of follow up (up to 6.8 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UC Participants (< 30 kg): Vedolizumab 100 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
UC Participants (< 30 kg): Vedolizumab 200 mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
CD Participants (< 30 kg): Vedolizumab 100 mg0/5 (0%)0/5 (0%)5/5 (100%)
CD Participants (< 30 kg): Vedolizumab 200 mg0/5 (0%)4/5 (80%)5/5 (100%)
UC Participants (>=30 kg): Vedolizumab 150 mg0/2 (0%)1/2 (50%)2/2 (100%)
UC Participants (>=30 kg): Vedolizumab 300 mg0/7 (0%)3/7 (42.9%)6/7 (85.7%)
CD Participants (>=30 kg): Vedolizumab 150 mg0/2 (0%)1/2 (50%)2/2 (100%)
CD Participants (>=30 kg): Vedolizumab 300 mg0/10 (0%)4/10 (40%)10/10 (100%)
UC Participants: Dose Escalated to Vedolizumab 300 mg0/12 (0%)4/12 (33.3%)12/12 (100%)
CD Participants: Dose Escalated to Vedolizumab 300 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Infectious mononucleosisInfections and infestations0/30/60/50/51/20/70/20/100/120/6
Post procedural haemorrhageInjury, poisoning and procedural complications0/30/60/50/50/20/71/20/100/120/6
Crohn's diseaseGastrointestinal disorders0/30/60/51/50/20/70/24/100/120/6
Clostridium difficile colitisInfections and infestations1/30/60/50/50/20/70/20/100/120/6
Colitis ulcerativeGastrointestinal disorders1/30/60/51/50/22/70/20/101/120/6
Abdominal painGastrointestinal disorders0/30/60/51/50/20/70/20/101/120/6
ColitisGastrointestinal disorders0/30/60/51/50/20/70/20/100/120/6
ExostosisMusculoskeletal and connective tissue disorders0/30/60/51/50/20/70/20/100/120/6
Rectal haemorrhageGastrointestinal disorders0/30/60/51/50/20/70/20/100/120/6
UrticariaSkin and subcutaneous tissue disorders0/30/60/51/50/20/70/20/100/120/6
Most frequent other events
Showing 10 of 198
Most frequent other events
EventUC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgUC Participants: Dose Escalated to Vedolizumab 300 mgCD Participants: Dose Escalated to Vedolizumab 300 mg
Crohn's diseaseGastrointestinal disorders0/30/60/52/50/20/70/23/100/124/6
PyrexiaGeneral disorders1/34/60/50/51/22/70/20/104/121/6
Abdominal painGastrointestinal disorders0/31/60/51/51/21/70/23/104/121/6
ArthralgiaMusculoskeletal and connective tissue disorders0/33/60/51/51/22/70/21/100/120/6
AsthmaRespiratory, thoracic and mediastinal disorders0/30/61/50/51/20/70/20/100/120/6
Blood iron decreasedInvestigations0/30/60/50/51/20/70/20/100/120/6
COVID-19Infections and infestations0/33/61/51/50/21/70/20/102/121/6
ChillsGeneral disorders0/30/60/50/51/20/70/20/100/120/6
Colitis ulcerativeGastrointestinal disorders1/33/60/50/50/22/70/20/106/120/6
DehydrationMetabolism and nutrition disorders0/31/60/50/50/20/71/20/100/120/6

Baseline characteristics

The enrolled set included all participants enrolled in the study.

Age, Customized
Age, Customized(Participants)UC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgTotal
Children (2-11 years)5756421333
Adolescents (12-17 years)0221653726
Sex: Female, Male
Sex: Female, Male(Participants)UC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgTotal
Female2324432525
Male3653642534
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgTotal
Hispanic or Latino022101006
Not Hispanic or Latino565510641051
Unknown or Not Reported010100002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UC Participants (< 30 kg): Vedolizumab 100 mgUC Participants (< 30 kg): Vedolizumab 200 mgCD Participants (< 30 kg): Vedolizumab 100 mgCD Participants (< 30 kg): Vedolizumab 200 mgUC Participants (>=30 kg): Vedolizumab 150 mgUC Participants (>=30 kg): Vedolizumab 300 mgCD Participants (>=30 kg): Vedolizumab 150 mgCD Participants (>=30 kg): Vedolizumab 300 mgTotal
American Indian or Alaska Native000000000
Asian000001012
Native Hawaiian or Other Pacific Islander000000000
Black or African American010020014
White5756854848
More than one race001001002
Unknown or Not Reported011100003
08

Study locations

23 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106-3322, United States
  • Nemours Childrens Specialty Care - Jacksonville
    Jacksonville, Florida 32207, United States
  • Children's Center for Digestive Healthcare
    Atlanta, Georgia 30342, United States
  • Columbia University Medical Center
    New York, New York 10031, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hopital Necker-Enfants Malades
    Paris, Île-de-France Region 75015, France
  • BAZ Megyei Korhaz es Egyetemi Oktatokorhaz
    Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrád megye 6720, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4032, Hungary
  • The Edmond and Lily Safra Children's Hospital - Sheba Medical Center
    Ramat Gan, Tel Aviv 52621, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Schneider Children's Medical Center of Israel
    Petach Tiqwa, 4920235, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Uniwersytecki Szpital Dzieciecy w Krakowie
    Krakow, Lesser Poland Voivodeship 30-663, Poland
  • Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski
    Rzeszów, Podkarpackie Voivodeship 35-302, Poland
  • Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi Osrodek Pediatryczny im Marii Konopnic
    Lodz, Łódź Voivodeship 91-738, Poland
  • Kharkiv Regional Clinical Children's Hospital
    Kharkiv, 61093, Ukraine
  • Barts and The London NHS Trust
    London, England E1 1BB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Apr 2025, 80 months.

Results were first posted in Mar 2026, 11 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 80 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 22, 2017
StartActual
Jul 30, 2018
Primary completionActual
Apr 3, 2025
CompletionActual
Jul 17, 2025
Results first posted
Mar 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03196427
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Jul 30, 2018
Primary completion
Apr 3, 2025
Completion
Jul 17, 2025
Results posted
Mar 13, 2026
Last update
May 13, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion